International Summit on Race Day Medication: EIPH and the racehorse
Coming to a consensus on treating exercise-induced pulmonary hemorrhage
Sep 01, 2011
The event was jointly sponsored by the American Association of Equine Practitioners (AAEP), the National Thoroughbred Racing Association (NTRA) and the Racing Medication and Testing Consortium (RMTC). Veterinarians, trainers and racing officials from the United States and various international racing jurisdictions, including Ireland, Hong Kong, the United Kingdom, South Africa, United Arab Emirates and Australia, participated in the discussions.
In North America, there are 38 different racing jurisdictions with medication rules that generally forbid the use of any race day medication except for the treatment of horses that experience EIPH. Furosemide has been used in racing for about 30 years, and from the beginning it has been controversial. The industry is polarized on this emotional issue.
"If you look at the issue of EIPH with a Salix lens, the discussion takes on a yes or no format; there is no opportunity for consensus," says Palmer. "We felt that the current paradigm for this issue was a dead-end street.
"The RMTC, NTRA and the AAEP convened the summit to refocus the discussion on the medical condition of EIPH and the racehorse rather than furosemide, per se. What do we know about the condition and what is the best way to manage it in the parimutuel environment?" says Palmer. "We felt that if we could address the race day medication issue from that standpoint, we might find some areas of consensus and move the discussion in a positive direction. Since the condition occurs in racing horses around the world and is regulated internationally without the use of furosemide on race day, we wanted to hear from people around the world—how they manage it, how they treat it and how they regulate it. We could get the international perspective and see what we might learn from their experience."